Cargando…

Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence

The use of probiotic starters can improve the sensory and health-promoting properties of fermented foods. In this study, we developed an anti-inflammatory probiotic starter, Limosilactobacillus reuteri EFEL6901, for use in kimchi fermentation. The EFEL6901 strain was safe for use in foods and was st...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Hee, Seong, Hyunbin, Kim, Ga Yun, Jo, Yu Mi, Cheon, Seong Won, Song, Youngju, Ryu, Byung Hee, Kang, Hee, Han, Nam Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656428/
https://www.ncbi.nlm.nih.gov/pubmed/34899643
http://dx.doi.org/10.3389/fmicb.2021.760476
_version_ 1784612279359111168
author Seo, Hee
Seong, Hyunbin
Kim, Ga Yun
Jo, Yu Mi
Cheon, Seong Won
Song, Youngju
Ryu, Byung Hee
Kang, Hee
Han, Nam Soo
author_facet Seo, Hee
Seong, Hyunbin
Kim, Ga Yun
Jo, Yu Mi
Cheon, Seong Won
Song, Youngju
Ryu, Byung Hee
Kang, Hee
Han, Nam Soo
author_sort Seo, Hee
collection PubMed
description The use of probiotic starters can improve the sensory and health-promoting properties of fermented foods. In this study, we developed an anti-inflammatory probiotic starter, Limosilactobacillus reuteri EFEL6901, for use in kimchi fermentation. The EFEL6901 strain was safe for use in foods and was stable under human gastrointestinal conditions. In in vitro experiments, EFEL6901 cells adhered well to colonic epithelial cells and decreased nitric oxide production in lipopolysaccharide-induced macrophages. In in vivo experiments, oral administration of EFEL6901 to DSS-induced colitis mice models significantly alleviated the observed colitis symptoms, prevented body weight loss, lowered the disease activity index score, and prevented colon length shortening. Analysis of these results indicated that EFEL6901 played a probiotic role by preventing the overproduction of pro-inflammatory cytokines, improving gut barrier function, and up-regulating the concentrations of short-chain fatty acids. In addition, EFEL6901 made a fast growth in a simulated kimchi juice and it synthesized similar amounts of metabolites in nabak-kimchi comparable to a commercial kimchi. This study demonstrates that EFEL6901 can be used as a suitable kimchi starter to promote gut health and product quality.
format Online
Article
Text
id pubmed-8656428
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86564282021-12-10 Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence Seo, Hee Seong, Hyunbin Kim, Ga Yun Jo, Yu Mi Cheon, Seong Won Song, Youngju Ryu, Byung Hee Kang, Hee Han, Nam Soo Front Microbiol Microbiology The use of probiotic starters can improve the sensory and health-promoting properties of fermented foods. In this study, we developed an anti-inflammatory probiotic starter, Limosilactobacillus reuteri EFEL6901, for use in kimchi fermentation. The EFEL6901 strain was safe for use in foods and was stable under human gastrointestinal conditions. In in vitro experiments, EFEL6901 cells adhered well to colonic epithelial cells and decreased nitric oxide production in lipopolysaccharide-induced macrophages. In in vivo experiments, oral administration of EFEL6901 to DSS-induced colitis mice models significantly alleviated the observed colitis symptoms, prevented body weight loss, lowered the disease activity index score, and prevented colon length shortening. Analysis of these results indicated that EFEL6901 played a probiotic role by preventing the overproduction of pro-inflammatory cytokines, improving gut barrier function, and up-regulating the concentrations of short-chain fatty acids. In addition, EFEL6901 made a fast growth in a simulated kimchi juice and it synthesized similar amounts of metabolites in nabak-kimchi comparable to a commercial kimchi. This study demonstrates that EFEL6901 can be used as a suitable kimchi starter to promote gut health and product quality. Frontiers Media S.A. 2021-11-25 /pmc/articles/PMC8656428/ /pubmed/34899643 http://dx.doi.org/10.3389/fmicb.2021.760476 Text en Copyright © 2021 Seo, Seong, Kim, Jo, Cheon, Song, Ryu, Kang and Han. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Seo, Hee
Seong, Hyunbin
Kim, Ga Yun
Jo, Yu Mi
Cheon, Seong Won
Song, Youngju
Ryu, Byung Hee
Kang, Hee
Han, Nam Soo
Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
title Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
title_full Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
title_fullStr Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
title_full_unstemmed Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
title_short Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
title_sort development of anti-inflammatory probiotic limosilactobacillus reuteri efel6901 as kimchi starter: in vitro and in vivo evidence
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656428/
https://www.ncbi.nlm.nih.gov/pubmed/34899643
http://dx.doi.org/10.3389/fmicb.2021.760476
work_keys_str_mv AT seohee developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT seonghyunbin developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT kimgayun developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT joyumi developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT cheonseongwon developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT songyoungju developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT ryubyunghee developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT kanghee developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence
AT hannamsoo developmentofantiinflammatoryprobioticlimosilactobacillusreuteriefel6901askimchistarterinvitroandinvivoevidence